Alzheimer's disease (AD) is a neurodegenerative disease that gradually impairs cognitive functions. Recently, there has been a conceptual shift toward AD to view the disease as a continuum. Since AD is currently incurable, effective intervention to delay or prevent pathological cognitive decline may best target the early stages of symptomatic disease, such as subjective cognitive decline (SCD), in which cognitive function remains relatively intact. Diagnostic methods for identifying AD, such as cerebrospinal fluid biomarkers and positron emission tomography, are invasive and expensive. Therefore, it is imperative to develop blood biomarkers that are sensitive, less invasive, easier to access, and more cost effective for AD diagnosis. This review aimed to summarize the current data on whether individuals with SCD differ reliably and effectively in subjective and objective performances compared to cognitively normal elderly individuals, and to find one or more convenient and accessible blood biomarkers so that researchers can identify SCD patients with preclinical AD in the population as soon as possible. Owing to the heterogeneity and complicated pathogenesis of AD, it is difficult to make reliable diagnoses using only a single blood marker. This review provides an overview of the progress achieved to date with the use of SCD blood biomarkers in patients with preclinical AD, highlighting the key areas of application and current challenges.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Objective: Previous studies demonstrated that diabetic stroke patient had a poor prognosis and excess activation of the complement system in the peripheral blood. In this study, the association of serum complement levels with prognosis of diabetic stroke was examined.Methods: Patients with acute ischemic stroke were recruited and were divided into two groups according to the history of diabetes. Baseline data on the admission including C3 and C4 were collected. Neurologic function at discharge was the primary outcome and was quanti ed by the National Institutes of Health Stroke Scale (NIHSS).Results: A total of 426 patients with acute ischemic stroke (116 diabetic stroke and 310 non-diabetic stroke) were recruited in this study. There were signi cant differences on hypertension, CHD, TG, HDL, FGB, C4, and mortality rate between two groups. Furthermore, the values of complement protein levels were divided into tertiles. In diabetic stroke group, serum C4 level at acute phase in the upper third was independently associated with NIHSS score at discharge and concurrent infection. This associations were not signi cant in non-diabetic stroke.Conclusion: High serum C4 level at admission, as an unique signi cant predictor, was associated with unfavorable clinical outcome in the diabetic stroke, independently of traditional risk factors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.